Porfolio

Ambit Biosciences is a privately held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer. The company also markets the industry's most comprehensive kinase profiling service through its KinomeScan Division. KinomeScan is a proprietary technology designed to screen small molecule libraries against large numbers of human kinases for the purpose of rapidly advancing drug candidates with best-in-class potency and selectivity. Ambit has multiple drug candidates in pre-clinical and clinical development, including AC220, a selective class III receptor tyrosine kinase inhibitor currently in Phase I for treatment of acute myeloid leukemia. The company has partnerships with Roche, Bristol-Myers Squibb, GlaxoSmithKline, Cephalon, and other leading organizations. http://www.ambitbio.com

Applied Genetic Technologies Corporation is focused on developing gene therapy products derived from adeno-associated virus (AAV) for the treatment of inherited and acquired diseases. http://www.agtc.com

A biopharmaceutical company that focuses on arginase inhibition to promote endothelial function. Increased expression/activity of arginase has been implicated in a broad spectrum of diseases such as pulmonary arterial hypertension (PAH), asthma, and lung fibrosis, making it an attractive therapeutic target. http://www.arginetix.com

BrainCells, Inc. (BCI) is a biopharmaceutical company focused on the development of breakthrough small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on pioneering research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, novel targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. http://www.braincellsinc.com

Elusys Therapeutics, Inc. is a privately held biopharmaceutical company focused on the development of targeted anti-infective therapeutics using proprietary Heteropolymer (HP) antibodies for the treatment of infectious disease. The company's HP antibody technology has demonstrated a unique ability to clear and destroy pathogens and provides a platform to develop a deep pipeline of novel drug candidates targeted against bacterial, viral, and fungal infections. http://www.elusys.com

Hydra Biosciences, a biopharmaceutical company based in Cambridge, Massachusetts, develops drugs to treat pain, inflammation, cardiovascular, and other diseases using its expertise in novel ion channels. Hydra Biosciences' proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. More information about Hydra Biosciences is available at: http://www.hydrabiosciences.com.

Inotek Pharmaceuticals Corporation is a multinational biopharmaceutical firm focused on discovery, research, and the development of novel pharmaceutical technologies with potential applications in critical care, surgery, trauma, transplantation, and auto-immune diseases. http://www.inotekcorp.com

LigoCyte Pharmaceuticals, Inc. is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system. Immunomodulatory drugs represent one of the most exciting areas of pharmaceutical research today, addressing the disease process itself rather than simply treating the resulting symptoms. LigoCyte is advancing its proprietary products into human clinical testing, positioning the company for continued growth and success in the biotechnology industry. http://www.ligocyte.com

Micromet, Inc. implements novel concepts in antibody therapy, creating new options for the treatment of cancer, inflammation and autoimmune diseases. Unique to Micromet is BiTE™ (Bispecific T-cell Engagers), a novel class of antibody derivatives, which stands out in terms of therapeutic potency and economy of production. Micromet's drug candidate portfolio includes a human antibody and various compounds from the BiTE™ family. http://www.micromet.de

NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat cancer, infectious diseases, autoimmune diseases, asthma, and dermatitis. For more information on the company, please visit http://www.nktrx.com.

Rib-X Pharmaceuticals, Inc. is a small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The company's underlying drug discovery engine is based on its proprietary high-resolution crystal structure of the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis. http://www.rib-x.com

Sequoia Pharmaceuticals, Inc. is engaged in the discovery and development of novel antiviral therapeutics, with a focus on developing new treatments for drug-resistant infectious diseases such as HIV/AIDS and HCV-induced hepatitis. http://www.sequoiapharmaceuticals.com

VaxInnate Corporation is exploiting a growing knowledge base about the field of innate immunity, which suggests that elements of the innate immune system initiate and control the adaptive immune response. VaxInnate hopes to produce a proprietary vaccine that triggers both the innate and adaptive immune response in a controlled fashion, with the potential for extremely high vaccine potency and specificity and a reduction or elimination of excessive inflammation problems. http://www.vaxinnate.com

Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. Our products incorporate a proprietary "sialic switch" technology to improve the anti-inflammatory properties of antibodies. http://www.virdante.com

VLST Corporation is a privately held biotechnology company focused on the discovery and development of therapeutics for the treatment of inflammatory and autoimmune diseases. Disease areas in which the company's technology may have utility include multiple sclerosis, lupus, cardiovascular disease, diabetes, and obesity. http://www.vlstcorp.com

Xencor, Inc. is focused on the field of antibody Fc engineering to significantly improve antibody potency, using its proprietary Protein Design Automation^® technology platform. The company is internally advancing both XPro™ protein therapeutic candidates and XmAb™ antibody drug candidates optimized for activity against biologically validated targets. http://www.xencor.com